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Abstract 365 
 366 
Autism spectrum disorder (ASD) risk is influenced by common polygenic and de novo 367 
variation. We aimed to clarify the influence of polygenic risk for ASDs and to identify 368 
subgroups of ASD cases, including those with strong acting de novo variants, in which 369 
polygenic risk is relevant. Using a novel approach called the polygenic transmission 370 
disequilibrium test, and data from 6,454 families with a child with ASD, we show that 371 
polygenic risk for ASDs, schizophrenia, and greater educational attainment is over 372 
transmitted to children with ASDs. These findings hold independent of proband IQ. We 373 
find that polygenic variation contributes additively to risk in ASD cases who carry a 374 
strong acting de novo variant. Lastly, we show that elements of polygenic risk are 375 
independent and differ in their relationship with phenotype. These results confirm that 376 
ASDs’ genetic influences are additive and suggest they create risk through at least 377 
partially distinct etiologic pathways. 378 
 379 
 380 
 381 
 382 
  383 
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Introduction 384 
 385 
Risk for autism spectrum disorders (ASDs) is strongly genetically influenced, and reflects 386 
several types of genetic variation1-7. Common polygenic variation, distributed across the 387 
genome, accounts for at least 20% of ASD liability2,5,8,9. De novo single nucleotide and 388 
copy number variants can strongly affect the individuals who carry them1,3,4, but account 389 
for less liability at a population level (< 10%)2. Over the last several years, the common 390 
polygenic and de novo influences on ASD risk have been increasingly well characterized, 391 
particularly in terms of the distribution of their phenotypic effects. Most consistently, 392 
ASD-associated de novo variants have been strongly linked to intellectual disability, as 393 
well as other indicators of global neurodevelopmental impact (e.g., seizures; motor 394 
delay)1,10. Indeed ASD-associated de novo mutations that yield protein truncations are far 395 
more commonly observed in global developmental delay than in autism itself11. 396 
 397 
Recent studies have suggested that the common polygenic component of ASDs has a 398 
different, perhaps surprising, relationship with cognition. Polygenic risk for ASDs has 399 
been positively associated with intelligence and educational attainment in several 400 
reports6,12-14. In other words, in the general population, greater common variant risk for 401 
ASDs is associated with higher IQ. These findings are difficult to interpret – on average, 402 
IQ in ASD is at least a standard deviation below the population mean1,15. Further, ASDs 403 
share approximately 25% of their common variant influences with schizophrenia, and 404 
schizophrenia itself shows a negative genetic correlation with IQ6,14. While genetic 405 
correlation analyses are not expected to be transitive, this particularly complex network 406 
of common variant associations has led to concerns about confounding resulting from 407 
ascertainment and case heterogeneity16.  408 
 409 
Here we attempt to clarify the influence of common variant risk for ASDs, and to better 410 
understand the subgroups of ASD individuals for whom polygenic variation is risk 411 
contributing. We thus sought to employ a robust family-based design that would be 412 
immune to many of the potential confounders that can arise in attempting to construct a 413 
well-matched case-control comparison. To advance this analysis we extended the 414 
transmission disequilibrium approach to encompass polygenic risk scores; we call the 415 
resulting methodology the polygenic transmission disequilibrium test (pTDT). Using 416 
pTDT we then show that common polygenic predictors of (i) ASDs, (ii) schizophrenia, 417 
and (iii) years of educational attainment are unambiguously associated with ASD risk, 418 
independent of the presence of intellectual disability in cases. We find that common 419 
polygenic variation still contributes to ASD risk in cases that carry a very strong acting 420 
de novo event. Lastly, we find that the three aforementioned polygenic risk factors have 421 
independent and distinct effects on phenotypic heterogeneity in ASD, suggesting that 422 
components of common polygenic variation also behave additively and operate through 423 
at least partially distinct etiologic pathways. 424 
 425 
Children are expected to inherit half of their parents’ risk alleles for a trait. This 426 
expectation forms the basis of several commonly used tests of genetic association. The 427 
classic transmission disequilibrium test, for example, examines the frequency with which 428 
single genetic variants are transmitted from parents to their children17. Variants 429 
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transmitted significantly more than half of the time from unaffected parents to children 430 
affected with some trait or condition are nominated for association with that trait – only 431 
the ascertainment on a trait in the offspring and the association of the allele with the trait 432 
introduces deviation from the 50-50 chance of inheriting either allele from a 433 
heterozygous parent. Transmission disequilibrium tests have several convenient 434 
properties. First, they are immune to confounding by ancestry. They are also less 435 
vulnerable to bias from other potential differences between cases and controls, such as 436 
socioeconomic background or other factors commonly related to case ascertainment since 437 
the ‘controls’ are, in effect, the perfectly matched untransmitted chromosomes. 438 
 439 
In this study, we extend the transmission disequilibrium test to polygenic risk scores and 440 
introduce the polygenic transmission disequilibrium approach. A polygenic risk score 441 
(PRS) provides a quantitative measure of an individual’s genome-wide common variant 442 
predisposition (or “risk”) for a trait (Online Methods: Polygenic Risk Scoring). PRS are 443 
normally distributed in the population, which means that some degree of common variant 444 
risk for complex traits like ASDs is present in all of us. Since a child has a 50% chance of 445 
inheriting either allele from a heterozygous parent, it is algebraically defined that the 446 
expected value of a child’s PRS for any trait will be equal to the average of their parents’ 447 
PRS (mid-parent PRS). This expectation is broken when offspring are specifically 448 
ascertained for a phenotypic deviation from their parents (Supplementary Figure 1), for 449 
example children who are much taller than their parents or children affected with ASD 450 
when their parents are not. In the example of ASD, we would then expect the affected 451 
child to have received more of their parents ASD risk alleles than expected by chance9. 452 
From that, the average offspring PRS for an ASD-associated trait would be greater than 453 
the average mid-parent PRS. By comparing ASD individuals’ PRS for various traits 454 
against those of their unaffected parents, one can unambiguously associate specific types 455 
of common variant risk (e.g., polygenic risk for schizophrenia, educational attainment) 456 
with ASDs, and query the subsets of cases in which those risk factors are most relevant.  457 
 458 
We used two independent ASD family cohorts to examine transmission of polygenic risk 459 
(Online Methods: Sample Description; Supplementary Table 1). The Simons Simplex 460 
Collection (SSC) is a resource of more than 2,500 families with a single child diagnosed 461 
with ASD18. No other family members to the level of first cousins had an ASD diagnosis. 462 
Genotype data were available for the parents, the affected child, and an unaffected sibling 463 
for 2,091 SSC families (quad families). An additional 493 SSC families had available 464 
data for the parents and the affected child alone (trio families). Most genotyped 465 
individuals in SSC were exome sequenced in previous studies (89.0%)4. Our independent 466 
Psychiatric Genomics Consortium ASD (PGC ASD) sample consisted of 3,870 467 
genotyped parent-child trios from the Psychiatric Genomics Consortium Autism Group 468 
(Supplementary Table 2). The PGC ASD cohort described here does not include 469 
individuals from the SSC, and the data set does not include exome sequence information. 470 
 471 
We calculated common polygenic risk for ASDs, educational attainment (EA) and 472 
schizophrenia (SCZ) for all genotyped family members in the SSC and PGC ASD 473 
datasets using a standard approach (Online Methods: Polygenic Risk Scoring)19. In 474 
addition to polygenic risk for ASD itself, we chose to examine polygenic risk for EA and 475 
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SCZ as those phenotypes have been most strongly linked to ASD in genome-wide genetic 476 
correlation studies6,14,20. To build the polygenic predictors, we used summary statistics 477 
from the largest independent genome-wide association studies of each phenotype 478 
(Supplementary Table 3). The discovery GWAS (including ASD) did not include any 479 
SSC or PGC ASD individuals. Using the calculated polygenic risk scores, we first 480 
examined properties of their distribution in the parents. Analyzing the SSC and PGC 481 
ASD cohorts separately, we did not observe any consistent correlations between the 482 
parents’ PRS, for any pair of PRS, and based on that no PRS-based evidence of 483 
assortative mating (Supplementary Note 1, Supplementary Tables 4, 5). We also found 484 
no evidence that the mothers and fathers of children with ASD differ with regard to the 485 
common variant risk that they carry (Supplementary Note 2, Supplementary Table 6). 486 
Lastly, there was no evidence that mid-parent polygenic risk differs by proband sex 487 
(Supplementary Note 3, Supplementary Table 7). 488 
 489 
The pTDT is a t-test asking whether the mean of the offspring PRS distribution is 490 
consistent with its parentally-derived expected value (Online Methods: pTDT). In brief, 491 
for each trio, one averages the parent PRS for a given trait to generate the mid-parent 492 
value, and then subtracts that value from the proband’s PRS for the same trait. To 493 
standardize and improve interpretability, we divide the resulting difference by the 494 
standard deviation of the (observed) mid-parent distribution. This yields the estimated 495 
pTDT deviation, and the pTDT then tests whether the average pTDT deviation across all 496 
offspring differs from zero. A mean pTDT deviation of 0.1 for the ASD PRS, for 497 
example, would indicate that the offspring’s ASD PRS is on average 0.1 standard 498 
deviations higher than that of their parents. 499 
 500 
Results 501 
Polygenic Transmission Disequilibrium  502 
 503 
For each of ASD, SCZ, and EA, we calculated the average pTDT deviation for each 504 
affected child in the SSC and PGC ASD, as well as for each unaffected sibling in the 505 
SSC. The primary pTDT results are shown in Figure 1a. In both the SSC and PGC ASD 506 
samples, polygenic risk for each of ASD, EA, and SCZ was significantly over transmitted 507 
to affected children (P < 1E-06 for all comparisons), but not to SSC unaffected siblings 508 
(P > 0.05 for all comparisons; Figure 1a). This means that common polygenic risk 509 
defined in GWAS studies of ASD, SCZ, and greater EA are each unambiguously 510 
associated with autism spectrum disorders. The results did not change when the SSC and 511 
PGC ASD samples were restricted to families of European ancestry (Supplementary 512 
Note 4; Supplementary Table 8, Supplementary Figures 2, 3). We repeated the 513 
analysis in the SSC and PGC ASD using a PRS for body mass index (BMI) – a polygenic 514 
risk category unassociated with ASD6 – as a negative control (Online Methods: 515 
Polygenic Risk Scoring). As expected, we found that neither ASD probands nor 516 
unaffected siblings over inherited BMI PRS (P > 0.05 for all comparisons) 517 
(Supplementary Table 9).  518 
 519 
The degree of polygenic over transmission did not differ between SSC and PGC ASD 520 
probands for any comparison (P > 0.05 for all comparisons; Supplementary Table 10), 521 
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so we combined the samples to improve the power of subsequent subgroup analyses. 522 
Using the combined data, each PRS is over transmitted to both male and female probands 523 
(P < 0.05 for all comparisons; Figure 1b). In Figure 1c, we also see that each of the three 524 
PRS are significantly, and equally, over transmitted to ASD cases with measured IQs in 525 
the intellectual disability range (IQ < 70, (Online Methods: pTDT; Supplementary 526 
Tables 11, 12) when compared with those without intellectual disability. Most probands 527 
in the intellectual disability group do not have an observed genetic event that might 528 
explain their low IQ, for example a de novo mutation from an ASD-associated class, and 529 
repeating the analysis in the low IQ SSC probands with de novo carriers removed did not 530 
change the observed associations (Online Methods: De novo variant analyses; 531 
Supplementary Table 13).  532 
 533 
Common and rare variant additivity  534 
 535 
In order to best interrogate additivity between common polygenic and rare, strong acting 536 
variation, we defined a group of de novo mutations of large effect (Supplementary 537 
Table 14). We previously identified a subclass of de novo protein truncating variants 538 
(contributing PTVs) responsible for almost all of the PTV association to ASDs21 (Online 539 
Methods: De novo variant analyses). As de novo copy number variants (CNVs) that 540 
delete a gene should have the same, if not greater, molecular impact as a PTV in that 541 
gene, we were motivated to investigate whether we could similarly refine ASDs’ 542 
association with de novo deletions (Online Methods: De novo variant analyses). In the 543 
SSC, we found that ASDs were strongly associated with de novo deletions from two 544 
categories: a) deletions that include a constrained gene predicted to be intolerant of 545 
heterozygous loss of function variation (probability of loss of function intolerance (pLI) ≥ 546 
0.9)22, and b) uncommon, large (≥ 500 kilobase) deletions that do not contain a 547 
constrained gene (from here: contributing CNV deletions; Supplementary Figure 4, 548 
Supplementary Figure 5).  549 
 550 
Together, these refined classes of de novo PTVs and deletions form a category of strong 551 
acting de novo variants (from here: contributing de novo variants (CDNVs); odds ratio 552 
(OR) = 3.91, P = 6.56E-20; case rate = 9.4%; control rate = 2.6%). Consistent with a 553 
hallmark of ASD-associated de novo variation, Figure 2a shows that the rate of CDNVs 554 
in SSC varies substantially based on the probands’ counts of co-occurring adverse 555 
neurodevelopmental outcomes, in this case the count of: delayed walking, a history of 556 
seizures, or intellectual disability (Online Methods: De novo variant analyses; 557 
Supplementary Table 15). ASD probands without any of those comorbid traits were 558 
more than 3 times (OR = 3.15; P = 3.88E-10) as likely to carry a CDNV than their 559 
unaffected siblings; ASD probands with all three of these comorbid traits were 560 
approximately 15 times as likely to carry a CDNV than their unaffected siblings (OR = 561 
15.05; P = 9.08E-10). Because de novo events observed in cases and controls differ with 562 
regard to their average severity23, their effect size cannot be directly estimated using the 563 
case-control carrier ratio. Using the male:female carrier approach described by De Rubeis 564 
et al.3, we estimate that, on average, the CDNVs defined here confer an approximate 20-565 
fold increase in risk for an ASD diagnosis (Online Methods: De novo variant analyses). 566 
Their effect size, however, likely varies as the male:female ratio of the carriers declines 567 
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with increasing neurodevelopmental comorbidities (Supplementary Table 16). In other 568 
words, the CDNVs seen in the ASD individuals with multiple comorbid 569 
neurodevelopmental traits are likely, on average, more deleterious than those seen in 570 
probands with ASD alone. 571 
 572 
Shown in Figure 2b, we used pTDT to determine whether polygenic risk for ASD, SCZ, 573 
and EA was also over transmitted to CDNV carriers (Online Methods: De novo variant 574 
analyses). ASD cases with a CDNV (n = 221 cases) indeed carried more polygenic risk 575 
for ASD and SCZ than expected based on parent background (P < 0.05 for both 576 
comparisons). There was no evidence of over transmission of EA PRS (P = 0.80), though 577 
a larger number of ASD cases with a CDNV will be required to differentiate a true null in 578 
this instance from an issue of power. Over transmission of the ASD and SCZ PRS 579 
provides clear evidence for additivity between common and rare variation in creating risk 580 
for ASDs. We did not see a difference in polygenic over transmission between probands 581 
with zero versus one or more co-occurring neurodevelopmental outcomes (P > 0.05 for 582 
all comparisons; Supplementary Table 17), further supporting the consistent influence 583 
of polygenic risk factors. 584 
 585 
Additivity among common polygenic risk factors  586 
 587 
In the context of three orthogonal risk distributions, each of which is associated with 588 
ASDs, one does not have to maintain an extreme position on any single distribution to 589 
carry a cumulatively uncommon amount of ASD risk (Figure 3a). For example, being in 590 
the top 20% of three uncorrelated ASD risk distributions would result in a cumulative 591 
amount of risk seen in less than 1% of people in the population (0.23=0.008).  592 
 593 
Common polygenic risk for ASDs, SCZ, and EA is partially correlated6. As shown in 594 
Figure 3b, however, we observed little evidence of correlation between the ASD, SCZ, 595 
and EA PRS in terms of either a) correlation at the mid-parent level, above the diagonal 596 
or b) correlation in the degree to which the scores were transmitted to the probands 597 
(pTDT deviation), below the diagonal. The lack of strong associations is likely a function 598 
of both ascertainment effects and attenuation due to limited predictive ability of the PRS.    599 
 600 
Given limited association between the three PRS, we were able to examine additivity 601 
among largely distinct common polygenic risk factors. First, we saw significant evidence 602 
that each of the three PRS were independently over transmitted (P < 2E-04 in all SSC + 603 
PGC ASD comparisons; Online Methods: Genetic heterogeneity; Supplementary 604 
Table 18). This means that ASD risk is influenced by elements unique to each of the 605 
scores, as well as by elements that are shared among them. Independent influences are 606 
further suggested by the scores’ relationship with proband IQ (Supplementary Table 607 
19). In Figure 3c, we show the association between each PRS and full scale proband IQ 608 
in European ancestry SSC probands, controlling for sex, presence of CDNVs, the other 609 
two PRS, and the first 10 principal components of ancestry (Online Methods: Genetic 610 
heterogeneity). The EA and SCZ PRS are associated with proband IQ in opposite 611 
directions, consistent with the patterns observed in the general population 612 
(Supplementary Table 19)14.  613 
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 614 
In addition to statistical evidence of unique contributions, the phenotypic associations 615 
suggest that the three PRS are influencing ASD risk through at least partially different 616 
processes. Polygenic risk for SCZ influences ASD liability in a manner that negatively 617 
influences cognition. Polygenic risk for EA influences ASD liability in a manner that 618 
positively influences cognition. These findings reinforce the idea that ASD heterogeneity 619 
is shaped not only by rare variants of strong effect, but also by diverse common variant 620 
risk factors acting through multiple biological pathways.   621 
 622 
Discussion 623 
 624 
Despite longstanding evidence for common polygenic influences on ASD risk, many 625 
have questioned those associations, particularly the recently published – and 626 
counterintuitive – findings from genetic correlation analysis. Using pTDT, we have 627 
shown an unambiguous association between ASD risk and the common polygenic 628 
influences on: ASDs themselves, schizophrenia, and greater educational attainment. 629 
These effects were evident in affected males and affected females, as well as ASD 630 
individuals with and without intellectual disability. Because of the strong correlation 631 
between the polygenic influences on educational attainment and intelligence14, this 632 
finding means that, on average, individuals with ASD and intellectual disability have 633 
inherited more IQ increasing alleles than their typically developing siblings. That 634 
association, which replicated in independent ASD cohorts and held in probands without 635 
an ASD-associated de novo event, will require further study. With regard to proband 636 
phenotype, the finding furthers existing questions of whether an IQ measured below 70 in 637 
someone with an ASD might be different in some ways from an IQ measured below 70 in 638 
someone without. With regard to better understanding the mechanisms through which 639 
genetic risk is conferred, we need to examine how and when certain amounts of risk are 640 
beneficial (e.g., a strong interest in the arts or sciences that increases one’s educational 641 
attainment), and how and when they are deleterious (e.g., an overwhelming interest in a 642 
topic that disrupts healthy and necessary activities). Genetic risk and phenotypic traits 643 
relevant to neuropsychiatric disease exist on continua24, for which effective research and 644 
treatment paradigms will likely need to account. 645 
 646 
These findings also highlight important differences between the common and rare variant 647 
contributors to ASD risk. Strong acting, de novo variant risk for ASDs impacts a limited 648 
subset of cases. The phenotypic preferences of those types of variants are now well 649 
established; they are associated with intellectual disability, seizures, and global 650 
neurodevelopmental impact1. Common variant risk factors, on the other hand, appear 651 
more pervasively influential among ASD cases. Common variant risk appears similarly 652 
relevant to ASD individuals with high and low IQ, and with and without a large acting de 653 
novo mutation. The common polygenic influences also appear comparatively 654 
neurologically gentle. They are, in many cases, in fact associated with better educational 655 
and cognitive outcomes in the population. These differences strongly suggest that de 656 
novo and common polygenic variation may confer risk for ASD in different ways. 657 
Particularly as common polygenic risk is the more consistent contributor to ASD liability 658 
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across cases, it will be critically important to take common variation into account in 659 
creating animal or stem cell models of ASD.  660 
 661 
The pTDT approach can be broadly used to interrogate and clarify polygenic 662 
relationships. As a family-based approach, pTDT is immune to ancestral stratification 663 
and is less likely to be confounded by other influences on case ascertainment, for 664 
example socioeconomic status. While pTDT achieves optimal power comparing offspring 665 
with parents, it can be easily adapted to compare probands and unaffected siblings, and 666 
its predictive ability will improve through additional methodological development and 667 
larger discovery sample sizes. A command line tool to assist with pTDT analysis is 668 
publically available at: https://github.com/ypaialex/ptdt. 669 
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Data Availability Statement  705 
The availability of the GWAS summary statistics we used to calculated PRS is detailed in 706 
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Figure 1 Legend ASD probands over inherit polygenic risk for ASD, schizophrenia, and 809 
greater educational attainment. Transmission disequilibrium is shown in terms of 810 
standard deviations on the mid-parent distribution ± 1.96 standard error (95% confidence 811 
intervals). P-values denote the probability that the mean of the pTDT deviation 812 
distribution is 0 (two-sided, one-sample t-test). (a) ASD probands over inherit ASD 813 
associated polygenic risk in the Simon Simplex Collection (SSC, n = 2,584), Psychiatric 814 
Genomics Consortium Autism Group (PGC ASD, n = 3,870), and combined cohorts (n = 815 
6,454). Unaffected siblings in SSC (n = 2,091) do not over inherit ASD associated 816 
polygenic risk. (b) Both male (n = 5,490) and female (n = 962) probands over inherit 817 
ASD associated polygenic risk in the SSC+PGC ASD combined cohort. (c) ASD 818 
probands with (n = 1,341) and without (n = 2,743) intellectual disability (full-scale IQ < 819 
70) over inherit ASD associated polygenic risk in the SSC+PGC ASD combined cohort. 820 
 821 
Figure 2 Legend Contributing de novo mutations are associated with adverse 822 
neurological and developmental outcomes and act additively with polygenic burden to 823 
influence ASD risk. (a) Simons Simplex Collection (SSC) probands are grouped by their 824 
count of the following: delayed walking (≥ 19 months); presence of seizures; intellectual 825 
disability (full-scale IQ < 70) (n = 1,476 with no outcomes; n = 719 with 1 outcome; n = 826 
134 with 2 outcomes; n = 16 with 3 outcomes). Contributing de novo variant (CDNV) 827 
rate is calculated by dividing the count of CDNVs by the count of individuals. The odds 828 
ratio (OR) was calculated via Poisson regression predicting CDNV count from 829 
case/control status for all controls (n = 1,736) and cases in the outcome category, 830 
controlling for maternal and paternal age at birth of the child. P-values above each 831 
diamond are from the Poisson regression and indicate the probability that the CDNV rate 832 
in cases is not different from the CDNV rate in controls. P-values between the diamonds 833 
are calculated from Poisson exact test and indicate the probability that there is no 834 
difference in CDNV rate between the two noted groups. Error bars are ± 1 standard error. 835 
(b) pTDT analysis for SSC CDNV proband carriers (n = 221). Transmission 836 
disequilibrium is shown in terms of standard deviations on mid-parent distribution ± 1.96 837 
standard error (95% confidence intervals). P-values denote the probability that the mean 838 
of the pTDT deviation distribution is 0 (two-sided, one-sample t-test).  839 
 840 
Figure 3 Legend (a) Additivity among orthogonal risk factors can yield high cumulative 841 
risk. (b) Polygenic risk scores (PRS) for ASDs, schizophrenia (SCZ), and educational 842 
attainment (EA) are not strongly associated at either the mid-parent level (above 843 
diagonal) or the pTDT deviation level (below diagonal). The table contains Pearson 844 
correlation coefficients and associated p-values indicating the probability with which the 845 
true correlation is 0. Mid-parent correlations are controlled for first 10 principal 846 
components of parental ancestry. PRS are from European ancestry SSC families (n = 847 
1,851). (c) Polygenic risk factors for ASD exhibit independent, distinct effects on IQ in 848 
European ancestry SSC probands (n = 1,674). P-values, which estimate the probability of 849 
no association between each PRS and IQ, are calculated from linear regression. We 850 
predicted full-scale IQ from each PRS, z-normalized following residualization for the 851 
other two PRS, CDNV presence/absence, proband sex, and the first 10 principal 852 
components of proband ancestry. Each panel displays the linear association between full-853 
scale proband IQ and the normalized PRS.  854 
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Online Methods 855 
 856 
Sample Description. The analytic cohorts are presented in Supplementary Table 1. The 857 
research specific to this study was approved by the Partners Healthcare Institutional 858 
Review Board. The Simons Simplex Collection (SSC) is a resource of more than 2,500 859 
families with a child diagnosed with an autism spectrum disorder (ASD)18. Informed 860 
consent and assent was provided for all subjects. Each member of the family was 861 
genotyped on one of the following platforms: Illumina Omni2.5, Illumina 1Mv3 or 862 
Illumina 1Mv11. We analyzed 2,091 SSC quads, defined as families with both parents, 863 
the proband, and a designated unaffected sibling genotyped, and 493 SSC trios, defined 864 
as families with both parents and the proband genotyped. Most SSC families were also 865 
whole exome sequenced to detect rare coding variation (82.7% of quads, an additional 866 
8.0% of quads without sibling sequencing; 91.1% of trios).  867 
The Psychiatric Genomics Consortium Autism Group (PGC ASD) sample 868 
consisted of parent-proband trios from the Psychiatric Genomics Consortium Autism 869 
Group (Supplementary Table 2). Our PGC ASD analytic sample excluded the SSC 870 
families present in the PGC ASD genome-wide association study (GWAS)20. The PGC 871 
ASD sample described here is accordingly independent from the SSC sample and 872 
included 3,870 parent-proband trios. In brief, the PGC ASD data included ASD trio 873 
cohorts from: Autism Center of Excellence UCLA (n = 215), Autism Genome Project (n 874 
= 2,254), Montreal/Boston Collection (n = 138), Johns Hopkins University (n = 764), and 875 
the Children’s Hospital of Philadelphia (n = 499)20. All genotype data (SSC and PGC 876 
ASD) were imputed using the 1000 Genomes reference panel and Ricopili pipeline, 877 
which are publicly available and have been reported on extensively19,25,26.  878 
Though trio approaches are broadly immune to confounding through ancestry, we 879 
isolated European-only subsets of both the SSC and PGC ASD samples to a) ensure that 880 
our primary results did not change in an ancestrally homogeneous subset of the data and 881 
b) conduct comparisons across probands or across parents, which might be sensitive to 882 
ancestry (as opposed to comparisons between probands and parents in a trio). In the SSC, 883 
we first selected probands with parent-reported white non-Hispanic ancestry (n = 1,912). 884 
We merged the genotype data from those individuals with the Hapmap III dataset27 and 885 
generated principal components of ancestry using GCTA28. Through visual inspection 886 
(Supplementary Figure 6), we defined an ancestrally European SSC subcohort, leaving 887 
1,851 probands (and, by extension, 1,851 families). We calculated principal components 888 
of ancestry distinctly within the derived SSC European ancestry subcohort and used these 889 
as covariates in the non-trio analysis (e.g., genotype to phenotype analyses among 890 
probands).  891 
Self-reported ancestry was not available for the PGC ASD samples. To 892 
conservatively isolate a European ancestry PGC ASD subcohort, we identified those 893 
families in which both parents were of European ancestry. To do so, we merged the PGC 894 
ASD parent data with Hapmap III and similarly generated principal components of 895 
ancestry using GCTA. By visual inspection, we identified European ancestry individuals, 896 
leaving 6,742 of the original 7,740 PGC ASD parents (Supplementary Figure 7). Both 897 
parents were of European ancestry in 3,209 families, and those families comprised the 898 
European ancestry PGC ASD subcohort. We again calculated principal components of 899 
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ancestry within the derived PGC ASD European ancestry subcohort for use as analytic 900 
covariates in non-trio analyses. 901 
 902 
Polygenic Risk Scoring. A polygenic risk score (PRS) provides a quantitative estimate 903 
of an individual’s genetic predisposition (“risk”) for a given phenotype based on common 904 
variant genotype data and independent GWAS results for the target phenotype (e.g., 905 
schizophrenia or educational attainment)29. The score provides a relative, not absolute, 906 
measure of risk. For example, individual A (PRSschizophrenia = 8) is at higher estimated 907 
genetic risk for schizophrenia than individual B (PRSschizophrenia = 6), but a PRS of 8 or 6 908 
is not independently interpretable.  909 
We calculated polygenic risk for ASD, educational attainment (EA), 910 
schizophrenia (SCZ) and body mass index (BMI) for all individuals with available 911 
genotype data in the SSC and PGC ASD datasets. To do so, we used summary statistics 912 
from the largest available, independent GWAS of each phenotype (Supplementary 913 
Table 3). None of the subjects in the SSC or PGC ASD cohort were included in any of 914 
the four GWAS discovery samples. We selected SCZ and EA because of their robust, 915 
well-replicated associations with ASD risk6,14,20. We selected BMI as a negative control 916 
due to its lack of association with ASD risk6. We used ASD summary statistics from a 917 
GWAS of a Danish population-based sample of 7,783 cases and 11,359 controls from the 918 
first 10 genotyping waves of the iPSYCH-Broad Autism project24. The SCZ summary 919 
statistics were from the 2014 GWAS of 36,989 cases and 113,075 controls from the 920 
Psychiatric Genomics Consortium19. The EA summary statistics were from a population-921 
based GWAS of years of schooling (n = 328,917, discovery and replication meta-922 
analysis, excluding 23andMe)12. The BMI summary statistics were from a population-923 
based GWAS of body mass index (n = 322,154, European ancestry meta-analysis)30.  924 
To construct the polygenic risk scores, we first gathered the summary statistics 925 
from the GWAS described above. The summary statistics included effect sizes and p-926 
values for each single nucleotide polymorphism (SNP) in the imputed GWAS analysis, 927 
typically approximately 10 million markers. We then employed the widely used Ricopili 928 
pipeline to generate the PRS19. In brief, Ricopili first removes SNPs within 500 kilobases 929 
of and correlated (r2 ≥ 0.1) with a more significantly associated SNP in the GWAS. We 930 
used the 1000 Genomes Reference panel to estimate SNP correlations25. This process 931 
typically reduces the SNP list to fewer than 300,000 markers. For complex, polygenic 932 
traits, only a small fraction of those SNPs remaining pass the genome-wide significance 933 
threshold of P = 5.00E-08; the majority of the signal resides in SNPs that do not pass the 934 
significance threshold and cannot be specifically identified 6,12,19,28. In order to maximally 935 
capture common, polygenic influence, we therefore relaxed the p-value threshold for 936 
SNPs in the PRS until doing so added more noise than signal (threshold options: P ≤ 1, 937 
5E-1, 2E-1, 1E-1, 5E-2, 1E-2, 1E-3, 1E-4, 1E-6, and 5E-8). We identified the optimal p-938 
value threshold as that which explained the most phenotypic variation for each trait. For 939 
the ASD PRS, we found that the threshold of P ≤ 0.1 explained the most case-940 
pseudocontrol variance in SSC (as the SSC does not have independent control data, we 941 
generated pseudocontrol genotypes from the untransmitted parental alleles)20,24. For the 942 
SCZ and EA PRS, we used the threshold identified by analyses accompanying the 943 
discovery GWAS as explaining the most variance12,19. In the PGC’s 2014 schizophrenia 944 
analyses, a p-value threshold of P ≤ 0.05 most commonly explained the most SCZ case-945 
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control variance in 40 leave-one-out analyses19. For educational attainment, constructing 946 
a PRS using a threshold of P ≤ 1 explained the most variance in number years of 947 
education achieved in an independent sample12. For BMI, constructing a PRS using a 948 
threshold of P ≤ 0.2 explained the most variance in phenotypic body mass index among 949 
cases in the Simons Simplex Collection (Supplementary Note 5). These thresholds 950 
create the strongest polygenic risk scores for ASD, EA, SCZ and BMI, leaving us 951 
maximally powered to investigate the relationship between these four traits and ASDs. 952 
Next, we excluded SNPs that were poorly imputed in either SSC or PGC ASD 953 
(info score < 0.6 in either cohort). The exception to this filtering rule was in SSC-specific 954 
analyses, (e.g., analysis of de novo variation) where our info threshold of 0.6 was the 955 
minimum in the SSC imputation only. For each trait, the polygenic risk scores for 956 
individuals in SSC and PGC ASD were then calculated as the product of the GWAS 957 
effect size (log odds or beta) at that SNP by the individual’s count of reference alleles at 958 
that SNP (0, 1 or 2), summed across all remaining markers. We implemented this scoring 959 
protocol using the score function in Plink31. If an individual was missing genetic data at a 960 
SNP in the summary statistics file, Plink calculated the expected score based on the 961 
cohort-wide allele frequency. 962 
 963 
pTDT. We define pTDT deviation as: 964 
 965 
𝑝𝑇𝐷𝑇 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
𝑃𝑅𝑆𝑐 − 𝑃𝑅𝑆𝑀𝑃
𝑆𝐷(𝑃𝑅𝑆𝑀𝑃)
 966 
 967 
where PRSC is the polygenic risk score for the child (proband or unaffected sibling). 968 
PRSMP is the mid-parent polygenic risk score: 969 
 970 
 971 
𝑃𝑅𝑆𝑀𝑃 =  
𝑃𝑅𝑆𝑚𝑜𝑡ℎ𝑒𝑟 + 𝑃𝑅𝑆𝑓𝑎𝑡ℎ𝑒𝑟
2
 972 
 973 
SD(PRSMP) is the standard deviation of the sample-specific mid-parent PRS. For 974 
example, in SSC analysis, the SD(PRSMP) was the standard deviation of the mid-parent 975 
PRS distribution in SSC parents. We chose to standardize the pTDT deviation to improve 976 
interpretability and to facilitate comparison between different PRS. We standardized by 977 
PRSMP instead of PRSC because we expect the parent PRS distribution to be a better 978 
proxy for the population PRS distribution. The approach can be adapted to PRS from 979 
unaffected siblings, but using mid-parent PRS improves statistical power 980 
(Supplementary Note 6, Supplementary Table 20). 981 
To evaluate whether the pTDT deviation is significantly different than 0, we 982 
defined the pTDT test statistic (tpTDT) as: 983 
 984 
𝑡𝑝𝑇𝐷𝑇 =
𝑚𝑒𝑎𝑛(𝑝𝑇𝐷𝑇 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛)
𝑆𝐷(𝑝𝑇𝐷𝑇 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛) √𝑛⁄
 985 
 986 
where n is the number of families included in the pTDT. We evaluate tpTDT as a two-987 
sided, one-sample t-test. 988 
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We performed pTDT using the ASD, EA, SCZ and BMI PRS described above in 989 
four groups: SSC probands (n = 2,584), SSC unaffected siblings (n = 2,091), PGC ASD 990 
probands (n = 3,870), and the combination of SSC and PGC ASD probands (n = 6,454). 991 
As described in the main text (Figure 1a), each of the ASD, EA, and SCZ PRS were 992 
significantly over transmitted from parents to probands, but not to unaffected siblings (P 993 
< 1E-06 for all parent to proband comparisons in either SSC or PGC ASD; P < 1E-15 for 994 
all parent to proband comparisons in combined SSC and PGC ASD; P > 0.05 for all 995 
unaffected sibling comparisons). In contrast, BMI PRS was not over transmitted to 996 
probands (P > 0.05 in both the SSC and PGC ASD). In a complementary permutation 997 
test, we randomly assigned case/control labels to the affected and unaffected children in 998 
SSC. We then counted the number of times that the simulated difference in ASD PRS 999 
between affected and unaffected SSC children exceeded the observed difference (86 of 1000 
1,000,000 permutations = 0.0086%), consistent with the primary results (those in Figure 1001 
1a). 1002 
In our primary associations (Figure 1a, Supplementary Table 8), there were no 1003 
statistically significant pTDT differences between the SSC and PGC ASD cohorts 1004 
(Supplementary Table 10). We accordingly combined SSC and PGC ASD for the 1005 
analyses stratified by sex and IQ to increase statistical power (Figures 1b, 1c). In SSC, 1006 
full scale IQ (FSIQ; SSC variable: sscfsiq) was derived from a number of scales and 1007 
available for almost all probands (99.8%). Those scales included but were not limited to 1008 
the Differential Ability Scales, Second Edition32; Mullen Scales of Early Learning33; and 1009 
Wechsler battery34. Our full scale SSC IQ estimates were taken from the SSC’s ‘full scale 1010 
deviation IQ’ variable when it was available, and ‘full scale ratio IQ’ when it was not35. 1011 
FSIQ was measured heterogeneously across the contributing PGC ASD cohorts 1012 
(Supplementary Table 2). To accommodate measurement differences, FSIQ was 1013 
converted to broad groups for PGC consortium-level analyses (for the most part, numeric 1014 
IQ values from PGC ASD were not available for this analysis). PGC ASD probands were 1015 
assigned FSIQ levels 1-4 as follows: (1) FSIQ < 35; (2) 35 ≤ FSIQ < 70; (3) 70 ≤ FSIQ < 1016 
90; (4) 90 ≤ FSIQ. In PGC ASD, 38.9% of probands had estimated IQ available. We 1017 
divided each of SSC and PGC ASD by presence/absence of intellectual disability (ID) in 1018 
the proband so that they could be analyzed together (SSC ID: IQ < 70; PGC ASD ID: IQ 1019 
= 1 or IQ = 2). We repeated the IQ stratified analyses in SSC and PGC ASD separately, 1020 
which further suggested no differences between the cohorts, despite the limited FSIQ 1021 
data available in PGC ASD (Supplementary Tables 11, 12). 1022 
 1023 
De novo variant analyses. We defined a group of de novo mutations strongly associated 1024 
with ASD risk (Supplementary Table 14). We performed this analysis exclusively in 1025 
SSC; we could not perform the analysis in PGC ASD because only common variant 1026 
(GWAS) data was available. Our previous work has identified a subclass of de novo 1027 
protein truncating variants (PTVs: frameshift variants, splice acceptor variants, splice 1028 
donor variants, nonsense variants) that are a primary source of association to ASD21. De 1029 
novo PTVs in this class are a) absent from the Exome Aggregation Consortium database, 1030 
a reference sample of over 60,000 exomes, and b) found within a gene predicted to be 1031 
intolerant of heterozygous loss of function variation (probability of loss of function 1032 
intolerance (pLI) ≥ 0.9)22. In the SSC, de novo PTVs in this class were found in 7.1% of 1033 
cases and 2.1% of unaffected siblings (P = 4.12E-14). PTVs outside of this contributing 1034 
 24 
class are unassociated with ASD risk (observed in 7.8% of cases and 6.9% of unaffected 1035 
siblings, P = 0.50) and are not associated with proband IQ (P = 0.76) (Supplementary 1036 
Figure 8). 1037 
 As detailed in the main text, de novo copy number variants (CNVs) that delete a 1038 
gene should have the same molecular impact as a PTV in that same gene. Contributing 1039 
CNV deletions were seen in 2.5% of SSC cases and 0.5% of SSC unaffected siblings (P = 1040 
1.80E-08). All other types of de novo deletions were observed in 1.7% of cases and 1.4% 1041 
of unaffected siblings, and were not associated with ASD risk (P = 0.48; Supplementary 1042 
Figure 5). The associations between CNV categories and ASD risk are presented in the 1043 
supplement and did not differ substantially when controlling for parental age at birth of 1044 
child (Supplementary Table 21). Contributing deletions outside of our defined class 1045 
were not associated with proband IQ (P = 0.34, Supplementary Figure 9). In contrast, 1046 
de novo duplications of constrained genes are not disproportionately associated with ASD 1047 
risk (P = 0.49; Supplementary Note 7; Supplementary Figure 10). 1048 
We identified a subset of de novo CNV deletions, primarily those containing loss 1049 
of function intolerant genes, that account for most of the category’s association to ASDs 1050 
(contributing CNV deletions; Supplementary Figure 4). Together, contributing PTVs 1051 
and contributing CNV deletions formed a strong acting de novo variant category in SSC, 1052 
known from here as contributing de novo variants (CDNVs). Multiple lines of evidence 1053 
suggest CDNVs are robustly associated with ASD risk. CDNVs were seen in 9.4% of 1054 
SSC cases (n = 221 of 2,346) that were both sequenced and genotyped and 2.6% of SSC 1055 
unaffected siblings (n = 45 of 1,736) that were both sequenced and genotyped (P = 1056 
6.56E-20). CDNVs were very strongly associated with proband IQ (P = 5.80E-06; 1057 
controlling for proband sex), while all other de novo PTVs and deletions (those not in the 1058 
CDNV category) were not associated with proband IQ (P = 0.44, controlling for proband 1059 
sex; Supplementary Figure 11).  1060 
As de novo variants are on average more severe when observed in ASD cases than 1061 
in controls23, we could not estimate the amount of ASD risk conferred by CDNVs 1062 
directly from the case-unaffected sibling odds ratio. As noted in the main text, we used 1063 
the male:female CDNV carrier ratio to re-estimate the effect size for the event class, as 1064 
described in De Rubeis et al., 2014. In brief, the approximately 4:1 male:female ratio 1065 
among ASD cases suggests a different ASD liability threshold for males and females in 1066 
the population. Regardless of whether that difference reflects etiology or ascertainment, it 1067 
results in a direct mathematical relationship between the expected effect size of an event 1068 
class and the male:female carrier ratio of cases. In the case of CDNVs, a variant class 1069 
observed twice as frequently in female probands than in male probands (17.4% v 8.5%; P 1070 
= 5.26E-06; Supplementary Figure 12), we estimate an OR of approximately 20 3. This 1071 
estimate exceeds that directly suggested by the CDNV case-control excess of 3.63.  1072 
We next examined the rate of CDNVs in SSC probands based on the number of 1073 
adverse proband co-occurring neurological and developmental outcomes (Figure 2a). 1074 
Previous studies have demonstrated that de novo PTVs and de novo CNVs are both 1075 
associated with intellectual disability (IQ < 70) in ASD probands and positively 1076 
associated with history of seizures1,15. Motor delays are an additional 1077 
neurodevelopmental co-morbitidy associated with autism spectrum disorder36. Here, we 1078 
defined motor delay for SSC probands as walking unaided at or after 19 months, the age 1079 
by which the great majority of children have begun to walk37. As hypothesized, motor 1080 
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delay, seizures, and low IQ were independently associated with CDNV rate in SSC 1081 
probands after controlling for proband sex (Supplementary Table 15). CDNV rate was 1082 
positively associated with the number of these adverse outcomes experienced by 1083 
probands (Figure 2a, Supplementary Table 16). The decreasing male:female ratio 1084 
among CDNV carriers as count of co-occurring neurodevelopmental outcomes increases 1085 
suggests that with increased count of neurodevelopmental comorbidities comes, on 1086 
average, increasingly severe de novo events (Supplementary Note 8, Supplementary 1087 
Table 16). Multiple lines of evidence, including associations with IQ, male:female carrier 1088 
ratio, and adverse co-occurring neurodevelopmental outcomes, suggest that CDNVs are 1089 
strongly associated with ASD risk.  1090 
Using pTDT, we evaluated polygenic transmission in probands carrying at least 1091 
one CDNV (Figure 2b, Supplementary Table 13). As this CDNV analysis is specific to 1092 
SSC, the polygenic risk scores generated for the CDNV analysis used info score cutoffs 1093 
from SSC imputation in order to increase the number of well-imputed SNPs retained for 1094 
PRS. We restricted our analysis to those families with genotyped parents and probands 1095 
with both genotype and exome sequence data (n = 2,346; n = 221 with CDNV). The 1096 
cohort of probands with a CDNV is too small to determine whether the difference in 1097 
transmission between probands that do and do not carry a CDNV is statistically 1098 
significant. We also analyzed whether polygenic over transmission was seen in a more 1099 
broadly defined set of de novo events (Supplementary Note 9, Supplementary Table 1100 
13). 1101 
 1102 
Genetic heterogeneity and proband phenotype. We analyzed whether polygenic risk 1103 
for ASD, EA and SCZ were each independently over transmitted to ASD cases. For each 1104 
of SSC (n = 2,584 trios), PGC ASD (n = 3,870 trios) and SSC & PGC ASD combined (n 1105 
= 6,454 trios), we performed a single logistic regression predicting proband/mid-parent 1106 
status from polygenic risk for 1) ASD, 2) EA and 3) SCZ. We confirmed that the over 1107 
transmission acts independently in each PRS (P < 2E-04 for all PRS in SSC + PGC ASD 1108 
cohort; Supplementary Table 18). 1109 
To calculate the relationship between proband polygenic risk and ASD IQ 1110 
(Figure 3c), we performed three separate linear regressions predicting full-scale proband 1111 
IQ from the three PRS. The three ASD IQ - PRS associations are from three linear 1112 
regressions predicting full-scale proband IQ from the residualized and z-normed PRS. 1113 
The other two PRS, CDNV presence/absence, proband sex, and the first 10 principal 1114 
components of proband ancestry were regressed out of each PRS before analysis. These 1115 
associations were performed in European ancestry Simons Simplex Collection probands 1116 
(n = 1,674). The results were consistent with previously published association between 1117 
the three polygenic risk scores and IQ in the general population (Supplementary Table 1118 
19)14. This relationship between polygenic risk and proband IQ holds when using mid-1119 
parent PRS and controlling for proband CDNV status (Supplementary Note 10, 1120 
Supplementary Table 22). 1121 
 1122 
 1123 
 1124 
 1125 
 1126 
 26 
Methods-only references 1127 
 1128 
25. Genomes Project, C., et al. An integrated map of genetic variation from 1,092 1129 
human genomes. Nature 491, 56-65 (2012). 1130 
26. Ricopili. Rapid Imputation Consortium Pipeline. 1131 
27. International HapMap, C., et al. Integrating common and rare genetic variation in 1132 
diverse human populations. Nature 467, 52-58 (2010). 1133 
28. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-1134 
wide complex trait analysis. American journal of human genetics 88, 76-82 1135 
(2011). 1136 
29. Wray, N.R., Goddard, M.E. & Visscher, P.M. Prediction of individual genetic risk 1137 
to disease from genome-wide association studies. Genome research 17, 1520-1138 
1528 (2007). 1139 
30. Locke, A.E., et al. Genetic studies of body mass index yield new insights for 1140 
obesity biology. Nature 518, 197-206 (2015). 1141 
31. Chang, C.C., et al. Second-generation PLINK: rising to the challenge of larger 1142 
and richer datasets. GigaScience 4, 7 (2015). 1143 
32. Elliott, C. Differential Ability Scales, (The Psychological Corporation, San 1144 
Antonio, TX, 2007). 1145 
33. Mullen, E. Mullen Scales of Early Learning, (American Guidance Service, Circle 1146 
Pines, MN, 1995). 1147 
34. Wechsler, D. Wechsler abbreviated scale of intelligence, (Psychological 1148 
Corporation, San Antonio, TX, 1999). 1149 
35. Chaste, P., et al. A genome-wide association study of autism using the Simons 1150 
Simplex Collection: Does reducing phenotypic heterogeneity in autism increase 1151 
genetic homogeneity? Biological psychiatry 77, 775-784 (2015). 1152 
36. Provost, B., Lopez, B.R. & Heimerl, S. A comparison of motor delays in young 1153 
children: autism spectrum disorder, developmental delay, and developmental 1154 
concerns. Journal of autism and developmental disorders 37, 321-328 (2007). 1155 
37. World Health Organization, T. WHO Motor Development Study: windows of 1156 
achievement for six gross motor development milestones. Acta paediatrica 450, 1157 
86-95 (2006). 1158 
 1159 
 1160 
